Serina Therapeutics Inc. is a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases. Serina Therapeutics Inc., formerly known as AgeX Therapeutics Inc., is based in HUNTSVILLE, Ala.
| Revenue (Most Recent Fiscal Year) | $0.06M |
| Net Income (Most Recent Fiscal Year) | $-11.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 16.20 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -9733.08% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -168.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.24 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.32 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.66 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.51 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.29 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 10.25M |
| Free Float | 8.41M |
| Market Capitalization | $51.15M |
| Average Volume (Last 20 Days) | 0.31M |
| Beta (Past 60 Months) | 0.67 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.50% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |